Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Average Target Price from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.1667.

CNTX has been the topic of several analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Maxim Group dropped their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Finally, Weiss Ratings lowered Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new position in shares of Context Therapeutics in the 2nd quarter valued at approximately $29,000. Bank of America Corp DE purchased a new stake in Context Therapeutics during the 2nd quarter worth approximately $30,000. Two Sigma Securities LLC increased its stake in Context Therapeutics by 388.7% during the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock valued at $34,000 after purchasing an additional 48,871 shares in the last quarter. Deutsche Bank AG acquired a new position in Context Therapeutics during the 2nd quarter valued at approximately $50,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Context Therapeutics in the first quarter worth $51,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

CNTX stock opened at $0.38 on Friday. Context Therapeutics has a one year low of $0.34 and a one year high of $3.62. The firm has a market cap of $35.15 million, a price-to-earnings ratio of -0.80 and a beta of 1.69. The firm has a 50-day simple moving average of $0.48 and a two-hundred day simple moving average of $1.48.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). As a group, equities analysts predict that Context Therapeutics will post -0.45 earnings per share for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted and immune-based treatments for solid tumors, with an emphasis on cancers that have limited treatment options. The company is headquartered in Philadelphia and conducts development activities through collaborations and clinical research networks.

Its lead investigational program is CTIM-76, a bispecific antibody designed to recognize Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.